Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Aragen Bioscience has received contract from National Institute of Allergy and Infectious Diseases (NIAID) to develop preclinical monoclonal antibodies to prevent and treat infectious diseases.
Subscribe to our email newsletter
Aragen Bioscience has received three subcontracts to produce and characteriza stable cell lines expressing antibodies against polio virus, pandemic influenza virus and Candida albicans, and to develop cell culture and purification processes to produce the antibodies for preclinical studies.
NIAID principal investigator for the contract Jon Mirsalis said working together, they will advance promising therapeutics to the clinic.
Aragen president and CEO Rick Srigley said these novel antibodies represent the next generation in infectious disease treatment and they look forward to supporting this important work in developing these new therapies.